A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7
|
作者：
Puglisi, Fabio [1 ]
Bisagni, Giancarlo [2 ]
Ciccarese, Mariangela [3 ]
Fontanella, Caterina [1 ]
Gamucci, Teresa [4 ]
Leo, Luigi [5 ]
Molino, Annamaria [6 ]
Silva, Rosa Rita [7 ]
Marchetti, Paolo [8 ,9 ]
机构：
[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy
[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy
[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy
[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[5] Azienda Osped Colli, Oncol Unit, Naples, Italy
[6] Univ Verona, Verona, Italy
[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy
[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy
[9] IDI IRCCS, Rome, Italy
来源：
FUTURE ONCOLOGY | 2016年 / 12卷 / 22期
关键词：
angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;
D O I：
10.2217/fon-2016-0295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.
引用
收藏
页码：2589 / 2602
页数：14
相关论文
共 50 条
  • [41] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Lobo, Christopher
    Lopes, Gilberto
    Baez, Odalys
    Castrellon, Aurelio
    Ferrell, Annapoorna
    Higgins, Connie
    Hurley, Erin
    Hurley, Judith
    Reis, Isildinha
    Richman, Stephen
    Seo, Pearl
    Silva, Orlando
    Slingerland, Joyce
    Tukia, Keleni
    Welsh, Catherine
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
  • [42] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Christopher Lobo
    Gilberto Lopes
    Odalys Baez
    Aurelio Castrellon
    Annapoorna Ferrell
    Connie Higgins
    Erin Hurley
    Judith Hurley
    Isildinha Reis
    Stephen Richman
    Pearl Seo
    Orlando Silva
    Joyce Slingerland
    Keleni Tukia
    Catherine Welsh
    Stefan Glück
    Breast Cancer Research and Treatment, 2010, 123 : 427 - 435
  • [43] First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study
    Mueller, Volkmar
    Ruhnke, Markus
    Hoffmann, Oliver
    Grafe, Andrea
    Tome, Oliver
    Fett, Werner
    Bruch, Harald-Robert
    Sommer-Joos, Ann-Katrin
    Schneeweiss, Andreas
    BREAST, 2021, 60 : 70 - 77
  • [44] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
    Al Mahmasani, Layal
    Amhaz, Ghid
    Abou Zeidane, Reine
    Chamseddine, Nathalie
    Hatab, Taha
    Sabbagh, Saad
    Charafeddine, Maya
    Assi, Hazem I.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer
    Katherine F. Croom
    Sohita Dhillon
    Drugs, 2011, 71 : 2213 - 2229
  • [46] Bevacizumab in the first-line treatment of metastatic breast cancer
    Cameron, David
    EJC SUPPLEMENTS, 2008, 6 (06): : 21 - 28
  • [47] First-line bevacizumab plus paclitaxel in Japanese patients with HER2-negative metastatic breast cancer: subgroup results from the randomized Phase III MERiDiAN trial
    Masuda, Norikazu
    Takahashi, Masato
    Nakagami, Kazuhiko
    Okumura, Yasuhiro
    Nakayama, Takahiro
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Tajima, Kosei
    Kashiwaba, Masahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (05) : 385 - 392
  • [48] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
    Tryfonidis, K.
    Boukovinas, I.
    Xenidis, N.
    Christophyllakis, C.
    Papakotoulas, P.
    Politaki, E.
    Malamos, N.
    Polyzos, A.
    Kakolyris, S.
    Georgoulias, V.
    Mavroudis, D.
    BREAST, 2013, 22 (06): : 1171 - 1177
  • [49] Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study
    Koszo, Renata
    Santha, Dra
    Budi, Laszl
    Erfan, Jzsef
    Gyorfy, Karoly
    Horvath, Zsolt
    Kocsis, Judit
    Landherr, Laszlo
    Hitre, Erika
    Mahr, Karoly
    Pajkos, Gabor
    Papai, Zsuzsanna
    Kahan, Zsuzsanna
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (03) : 505 - 511
  • [50] Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer
    Kevin R. Fox
    Current Oncology Reports, 2009, 11 : 5 - 7
12345